

# PRE RELEASE



EURAZEO.COM

PARIS, APRIL 11, 2016

## EURAZEO INVESTS IN NOVACAP, A LEADING GLOBAL PHARMACEUTICAL AND CHEMICALS COMPANY

Eurazeo today announced the signing of an agreement to invest in the Novacap group, a global player in the pharmaceutical and chemicals industry, for an enterprise value of €654 million (together with a maximum additional payment of €30 million in 2018 depending on the company's performance). By investing €160 million in equity, Eurazeo will become the majority shareholder with 67% of the capital, alongside Mérieux Développement (9%), Ardian (18%) and management (6%). Pending the approval of the regulatory authorities, the transaction should be completed by the summer.

Novacap is an international group that produces and distributes Active Pharmaceutical Ingredients (APIs) and essential chemicals products that are used in everyday applications such as aspirin, paracetamol, other APIs, salicylic acid, para-aminophenol, soda ash, sodium bicarbonate, phenol, oxygenated solvents and ferric chloride.

Novacap enjoys leading positions in growing end-markets, such as pharmaceutical & healthcare, cosmetics & fragrances, food & feed, home care and environment. The group is an industry leader across a wide range of products (e.g. No.1 in aspirin and salicylic acid globally, No.2 in paracetamol and sodium bicarbonate in Europe). It benefits from a solid European platform complemented by a well-established presence in Asia and an increasing footprint in North America. With over 750 customers across more than 80 countries, Novacap generated revenue of €634 million in 2015. Headquartered in Lyon (France), Novacap employs around 1,600 people across 14 industrial facilities worldwide and has a global commercial network. The company has flourished in recent years, with significant EBITDA growth from €45.6 million in 2010 (9.7% margin) to €91.5 million pro forma in 2015 (14.4% margin).

The common goal is to accelerate the group's growth by bolstering its position in five target markets, which combine both resilience and high growth, and by continuing to develop additional products for its current portfolio, particularly high added-value specialty products such as APIs, sodium bicarbonate or oxygenated solvents. To achieve this, Novacap will draw on its ability to innovate and an external growth policy based on partnerships and targeted acquisitions, mainly in the pharmaceutical and cosmetics industries. This will also help to boost its international coverage, both industrially and commercially.

### Virginie Morgon, deputy CEO of Eurazeo, stated:

*"We are delighted to be able to support Novacap in the next phase of its development. Its know-how, ability to innovate and technological excellence will provide Novacap, which is already world no. 1 in most of its sectors, with substantial growth potential in very buoyant and resilient end-markets such as the pharmaceutical or cosmetics industries that benefit from long-term trends (population ageing, development of the middle classes in emerging countries). This is what we are looking for in our investments. Our partnership with Mérieux Développement, combined with our international network, particularly in the United States and China where Novacap is present, will enable us to accompany the group in the future stages of its transformation into a global life sciences leader."*

## **Pierre Luzeau, Chairman of Novacap, added:**

*“We have chosen Eurazeo and Mérieux Développement to accompany us, alongside Ardian, in this new phase for our Group. The support of a long-term shareholder such as Eurazeo will enable us to speed up our growth, while boosting our international reach. Eurazeo and Mérieux Développement share our convictions regarding our business and its growth potential and will provide us not only with their financial support but also the networks and experience that we need to pursue our development based on organic and external growth.”*

\*\*\*

## **About Eurazeo**

With a diversified portfolio of 5 billion euros in assets, Eurazeo is one of the leading listed investment companies in Europe. Its purpose and mission is to identify, accelerate and enhance the transformation potential of the companies in which it invests. The Company covers most private equity segments through its four business divisions – Eurazeo Capital, Eurazeo Croissance, Eurazeo PME and Eurazeo Patrimoine. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term. Eurazeo is notably either a majority or key shareholder in AccorHotels, ANF Immobilier, Asmodee, Desigual, Elis, Europcar, Fintrax, Foncia, InVivo NSA, Les Petits Chaperons Rouges, Moncler, and smaller companies, including the investments of Eurazeo PME and Eurazeo Croissance.

Eurazeo is listed on Euronext Paris.

ISIN: FR0000121121 - Bloomberg: RF FP - Reuters: EURA.PA

## **About Mérieux Développement**

Mérieux Développement is an affiliate of Institut Mérieux, which employs around 15,000 employees worldwide, with consolidated revenues exceeding 2.4 billion Euros in 2015. Mérieux Développement is an evergreen fund specialized in the healthcare and nutrition sectors, conducting private equity and venture capital transactions on a global basis. Mérieux Développement brings its expertise and international network to enable entrepreneurs to disrupt and create new markets.

## **About Ardian**

Ardian is an independent private investment company with assets of US\$55bn managed or advised in Europe, North America and Asia. The company, which is majority-owned by its employees, keeps entrepreneurship at its heart and delivers investment performance to its global investors while fueling growth in economies across the world. Ardian's investment process embodies three values: excellence, loyalty and entrepreneurship. Ardian maintains a truly global network, with more than 410 employees working through twelve offices in Paris, London, Frankfurt, Milan, Madrid, Zurich, New York, San Francisco, Beijing, Singapore, Jersey, Luxembourg. The company offers its 470 investors a diversified choice of funds covering the full range of asset classes, with Ardian Fund of Funds (primary, early secondary and secondary), Ardian Private Debt, Direct Funds (including Ardian Mid Cap Buyout, Ardian Expansion, Ardian Growth and Ardian Co-Investment), Ardian Infrastructure, Ardian Real Estate and made to measure mandates with Ardian Mandates.

|                                    |                   |  |
|------------------------------------|-------------------|--|
| <b>Eurazeo financial timetable</b> | May 12, 2016      | Shareholders' Meeting<br>Q1 2016 revenue |
|                                    | July 27, 2016     | H1 2016 revenue                          |
|                                    | November 10, 2016 | Q3 2016 revenue                          |

#### EURAZEO CONTACTS

CAROLINE COHEN  
DIRECTOR INVESTOR RELATIONS  
E-mail: ccohen@eurazeo.com  
Tel: +33 (0)1 44 15 16 76

SANDRA CADIOU  
DIRECTOR OF COMMUNICATIONS  
E-mail: scadiou@eurazeo.com  
Tel: +33 (0)1 44 15 80 26

#### PRESS CONTACT

HAVAS WORLDWIDE PARIS  
RENAUD LARGE  
E-mail: renaud.large@havasww.com  
Tel: +33 (0)1 58 47 96 30  
+33 (0)6 33 49 36 06

For further information, please visit our website: [www.eurazeo.com](http://www.eurazeo.com)

Follow us on [Twitter](#), [LinkedIn](#), and [YouTube](#)